We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Stool Tests Rapidly Predict H. pylori Antibiotic Resistance

By LabMedica International staff writers
Posted on 11 Nov 2021
Print article
Image: Scanning Electron Micrograph of Helicobacter pylori: antibiotic resistance can be profiled using next generation sequencing (Photo courtesy of Juergen Berger / Science Photo Library)
Image: Scanning Electron Micrograph of Helicobacter pylori: antibiotic resistance can be profiled using next generation sequencing (Photo courtesy of Juergen Berger / Science Photo Library)
Helicobacter pylori eradication rates have declined in concert with rising antimicrobial resistance worldwide. There is a need for rapid accurate, reliable antibiotic resistance testing, especially in refractory cases.

Culture-based susceptibility testing requires endoscopic gastric biopsy, with resultant inconvenience and costs. Molecular testing using next generation sequencing (NGS) of stool potentially allows rapid prediction of resistance to all six commonly used antimicrobials.

Clinical Scientists at the Rhode Island Hospital (Providence, RI, USA) and their colleagues compared the accuracy of NGS with gastric biopsy for identifying H. pylori antibiotic resistance in 262 patients scheduled for upper endoscopy at four clinical practices. Two gastric biopsies were taken for NGS and a spontaneously passed stool specimen was also obtained within two weeks of endoscopy, but before starting treatment for H. pylori. H. pylori was confirmed in biopsies by PCR followed by NGS. H pylori in stools was confirmed by fecal antigen test and PCR. Stool samples positive by at least two stool tests were also examined by NGS to predict resistance to amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin.

The investigators reported that 73 (29%) patients were H. pylori positive by stool testing; two had insufficient gastric DNA for analysis. Of the 71 evaluable cases identical results for stool and biopsy samples were obtained for all six antibiotics in 65 (91.5%). In six cases there was mismatch between gastric and stool results; in four cases this was due to one antibiotic-associated mutation difference. For 70.4% of gastric biopsies, there was at least one resistance-associated mutation. Only 21 (29.6%) had no mutations. Results for stool were similar: 50 cases (68.5%) had at least one resistance-associated mutation and 23 (31.5%) had no mutations. The concordance between stool and gastric biopsies for individual antibiotics ranged from 89% (metronidazole) to 100%.

Steven Moss, MD, a gastroenterologist and senior author of the study, said, “Culture-based susceptibility testing requires endoscopic gastric biopsy, with resultant inconvenience and costs. It is now possible to rapidly obtain susceptibility data without endoscopy.”

The authors concluded that profiling H. pylori antibiotic resistance by NGS from stool samples provides rapid results highly comparable to those obtained from gastric biopsies. Using NGS to determine H. pylori antibiotic resistance using stool obviates the cost, inconvenience and risks of endoscopy for patients in whom resistance profiling is needed. The study was presented at the 2021 Virtual Meeting of the American College of Gastroenterology (ACG) held October 22-27, 2021.

Related Links:
Rhode Island Hospital


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.